将去甲基化药物与现货型 CD70 靶向嵌合抗原受体工程化自然杀伤 T 细胞协同用于治疗急性髓系白血病
Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of a
65.3分
★★★☆☆
站内排序·非疗效
FRONTIER PAPERS
MEMBER ACCOUNT
登录成功会直接打开下一页。